top of page
Natco Pharma

CMP

813

Buy

Rating

Natco Pharma

Result Update (Q1 FY21)

August 13, 2020 at 8:05:14 PM

Quick Update

Natco Pharma reported consolidated revenue of Rs. 563.40 cr up 14.4% Y-o-Y basis from Rs. 492.30 cr reported in Q1 FY20. Increase in revenue was on account of increase in exports and formulations business. EBITDA for the quarter stood at Rs. 171.10 cr down 10.6% Y-o-Y basis with EBITDA margins of 30.4% in Q1 FY21. The company reported PAT of Rs. 122.10 cr down 14.5% Y-o-Y basis. Profitability was impacted primarily due to lower oncology segment revenue during the quarter. Natco Pharma also declared an interim dividend of Rs. 1.25 per share for the quarter ended June, 2021.

The management is confident of achieving 25% eps growth in the current financial year based on order book and product pipeline outlook. However, sales mix in the coming quarter could impact the margins this financial year. Taking 25% eps growth values the company at 25.9x E FY21 earnings of ~Rs. 572 cr which is a premium valuation to its competitors. However, there are various green shoots such as Revlimid and other agro chemical products which put the company in better position to achieve higher profitability FY22 onwards. We opine investors to Buy based on management’s ability to carve out niche in each business segment it operates with a horizon of 18 - 24 months.

Download the full update

Other recent updates

white pmsec (1).png

Resources

Registered Office: 701, PJ Towers, Dalal Street, Fort, Mumbai 400001.

Corporate Office: 411 Atlantic Commercial Towers, RB Mehta Road, Ghatkopar (E), Mumbai-400077

Pankaj Mangaldas Securities: SEBI Reg. No.: INZ000206433 | CDSL: IN-DP-1662015 | CIN: U67120MH1998PTC116967 | GSTIN: 27AABCP0578N1Z0 | PAN: AABCP0578N

Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Attention Investors: Prevent unauthorized transactions in your demat account. Update your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your demat account directly from CDSL on the same day. Prevent unauthorized transactions in your trading account. Update your mobile numbers/email address with your stock brokers. Receive information of your transactions directly from the Exchange on your mobile/email at the end of the day. This is issued in the interest of investors. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund, etc...), you need not undergo the same process again when you approach another intermediary. As a business we don't give stock tips, and have not authorized anyone to trade on behalf of others. 

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

“Attention Investors

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.......... Issued in the interest of Investors"

Filing compliant on SCORES – Easy & quick

a. Register on SCORES portal

b. Mandatory details for filing complaints on SCORES I. Name, PAN, Address, Mobile Number, E-mail ID

c. Benefits: i. Effective Communication ii. Speedy redressal of the grievances 

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Languages. BSENSE

Compliance officer: Urvi Pokar | Email: compliance@pmsec.in

For any grievance/dispute contact us at Email:  grievance@pmsec.in

bottom of page